Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Non-Current Liabilities: 2015-2025

Historic Total Non-Current Liabilities for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $35.8 million.

  • Aytu Biopharma's Total Non-Current Liabilities rose 44.73% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 44.73%. This contributed to the annual value of $42.1 million for FY2025, which is 49.72% up from last year.
  • Per Aytu Biopharma's latest filing, its Total Non-Current Liabilities stood at $35.8 million for Q3 2025, which was down 15.00% from $42.1 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Total Non-Current Liabilities ranged from a high of $111.5 million in Q1 2021 and a low of $14.4 million during Q1 2024.
  • Over the past 3 years, Aytu Biopharma's median Total Non-Current Liabilities value was $28.2 million (recorded in 2024), while the average stood at $39.5 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 190.88% in 2021, then slumped by 85.37% in 2024.
  • Over the past 5 years, Aytu Biopharma's Total Non-Current Liabilities (Quarterly) stood at $110.0 million in 2021, then fell by 21.96% to $85.8 million in 2022, then tumbled by 60.15% to $34.2 million in 2023, then tumbled by 37.40% to $21.4 million in 2024, then soared by 44.73% to $35.8 million in 2025.
  • Its last three reported values are $35.8 million in Q3 2025, $42.1 million for Q2 2025, and $18.6 million during Q1 2025.